The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Addressing the underrepresentation of elderly individuals in myeloma clinical trials
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center & University of Miami, Miami, FL, comments on the challenges of including older patients in clinical trials for multiple myeloma. Prof. Landgren highlights that the average age of onset for myeloma is 70, and 95% of patients are 50 years or older, making it essential to consider real-world data from large populations to generate insights on the effectiveness of treatments. He believes that with the introduction of modern therapies, older patients can now benefit, with the hope that this may lead to improved outcomes and potentially similar lifespans to those without myeloma. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
